Professor Morand is Head of the School of Clinical Sciences at Monash Health, Monash University's largest clinical school.
He is a specialist rheumatologist, and Head of the Monash Health Rheumatology Unit, the largest in Australia. He specalises in research and clinical care of systemic lupus erythematosus, as well as complex rheumatic diseases and rheumatoid arthriitis. He is founder of the Monash Lupus Clinic, Australia's largest Lupus-focussed research-grounded clinic for patients with SLE, a founding member of the Australian Lupus Registry & Biobank, and Chair of the AsiaPaciifc Lupus Collaboration.
Professor Morand is Head of Rheumatology, Monash Health.
Professor Morand has served on the board of the Australian Rheumatology Association and is a member of the Scientific Advisory Board of its Research Trust.
Consulting and research collaboration experience with international biotech and Pharma companies including AstraZeneca, Janssen, BMS, UCB, Pfizer, Eli Lilly, GSK, CSL.
Special interests include SLE outcome measures, trials, translational research and biomarkers.
Professor Morand's key interests are clinical outcome measurement ad biological profiling in SLE, and the actions of glucocorticoid induced proteins on the immune system.
His group has pioneered the development of treat-to-target outcome measures in SLE, via the AsiaPacific Lupus Collaboration, which has over 1800 patients under study.
Biomarker studies in SLE are also a major interest ,with 000s of samples linked to longitudinal clincial data archived in the Australian Lupus Registry & Biobank, headquartered at Monash.
His lab group discovered the role in rheumatic disease of four glucocorticoid-regulated proteins. Most recently his group defined the role of GILZ in RA, Th17 pathways, B cell activation, and lupus, and are working on exploting its actions to develop a safe glucocortioid mimic.